Ask AI
ProCE Banner Activity

CE / CME

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

Video

In this certified on-demand webcast, experts discuss evidence-based strategies for PARP inhibitors as single agents and combination approaches with androgen receptor signaling inhibitors for the management of metastatic castration-resistant prostate cancer.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 19, 2025

Expiration: December 18, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson and Pfizer Inc.

Johnson & Johnson

Pfizer, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals caring for patients with metastatic castration-resistant prostate cancer.

Program Learning Goal

This activity aims to elevate learners' knowledge and competence in applying PARP inhibitor-based treatment strategies to improve patient outcomes with mCRPC. By deepening their utilization of biomarkers in guiding PARPi selection, aligning clinical practice with recent data and best practices, and managing PARPi-associated adverse events, learners will be better equipped to make informed clinical decisions that enhance patient outcomes and tailor care to individual patient needs.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Implement best practices in testing and interpreting results, including DNA damage repair alterations, understanding the application to therapy selection

  • Describe the medical need and rationale for PARP inhibitors and PARP inhibitor-based combinations in mCRPC, evaluating clinical data ​

  • Initiate therapy with PARP inhibitor–based combination regimens for the treatment of patients with prostate cancer, taking into account recent guideline updates, expert recommendations, and recent data, including patient subgroup data​

  • Appropriately mitigate and manage adverse events associated with PARP inhibitor combination regimens to improve quality of life, adherence, and outcomes in patients with prostate cancer​

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Neeraj Agarwal, MD, FASCO, has no relevant financial relationships to disclose.

Karim Fizazi, MD, PhD: consultant/advisor/speaker: Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Clovis, CureVac, Daiichi Sankyo, Janssen, MacroGenics, Merck Sharp & Dohme, Novartis/Advanced Accelerator Applications, Orion, Pfizer, Sanofi.

Rana R. McKay, MD, FASCO: consultant/advisor/speakers: Ambrx, Arcus, Artera, AI, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostic, Boundless Bio, Bristol Myers Squibb, Calithera, Caris, Daiichi Sankyo, Dendreon, Exelixis, Johnson & Johnson, Lilly, Neomorph, Nimbus, Novartis, Oncternal, Pfizer, Precede, Sanofi, SeaGen, Sorrento Therapeutics, Sumitomo Pharma, Telix, Tempus.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 19, 2025, through December 18, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/67167f3d10da3.png

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.